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ABSTRACT 
Objective: Juvenile Idiopathic Arthritis (JIA) is an autoimmune, inflammatory disease with 
involvement of innate and adaptive immune responses. However, the role of neutrophils in 
JIA pathogenesis remains unclear. This study aimed to identify and validate neutrophil gene 
expression signatures in JIA using public microarray datasets and new clinical samples. 
Methods: Three suitable datasets were analysed by significance analysis of microarray 
(SAM) and Ingenuity. Neutrophils and PBMCs were isolated from a new cohort of JIA 
patients and healthy paediatric controls (HC). Gene expression was validated using qPCR. 
Serum concentrations of proteins were measured using ELISA.  Low density granulocytes 
(LDGs) in JIA and HC PBMCs were quantified by flow cytometry using forward/side-scatter 
properties. 
Results: Ingenuity identified transcriptional regulation (FDR <0.05) by G-CSF, GM-CSF and 
IL-8 along with expression of neutrophil granule protein genes including elastase, 
myeloperoxidase, MMP8 and MMP9 in datasets from JIA PBMCs. LDG counts were 
elevated in JIA compared to HC (2.5% vs 1.4% p=0.007). Transcripts for MMP8 (p=0.005), 
MPO (p=0.0124) and FCGR1B (p=0.0417) were significantly higher in JIA compared to HC 
neutrophils. MMP9 protein levels were lower in sJIA (355.95ng/ml ±250.03ng/ml) patient 
sera compared to HC (675.41ng/ml ± 181.17ng/ml; p=0.007), but levels of elastase, 
myeloperoxidase and MMP8 were not significantly different.  
Conclusion: LDGs are elevated in JIA and contribute to the transcriptomic profile of JIA 
PBMCs. JIA neutrophils express higher levels of MMP8 and FCGR1B which may be 
implicated in disease pathology through the release of proteases and reactive oxygen 
metabolites, which cause systemic inflammation and damage to joints. 
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INTRODUCTION 
Juvenile Idiopathic Arthritis (JIA)1is a leading cause of rheumatic disease in childhood, 
encompassing a heterogeneous group of conditions characterised by joint inflammation of 
unknown origin persisting for over a period of six weeks[1, 2]. Presentation occurs in early 
childhood before the age of sixteen. JIA has been reported as one of the leading causes of 
both long and short-term disability amongst children, affecting approximately 10 in every 
100,000 children[1, 2]. The International League of Associations for Rheumatology (ILAR) 
classifies JIA into a number of clinical subtypes, including polyarticular (pJIA); oligoarticular 
(oJIA), systemic (sJIA), enthesitis related JIA, psoriatic JIA and undifferentiated arthritis [3, 
4]. Both pJIA and oJIA are the predominant forms, accounting for over half of presenting 
cases within the UK with patients [5]. While all subtypes of JIA tend to present with a clinical 
manifestation of localised inflammation in the joints, sJIA is also characterised by a range of 
extra-articular features, including fever, rash, and hepatosplenomegaly, many of which have 
been associated with growth disorders leading to disability amongst patients[6]. sJIA is 
considered a more acute and severe subtype of JIA, and it is estimated that approximately 
10% of individuals suffering from sJIA progress to macrophage activation syndrome (MAS), 
which can be fatal[7].  
 
The presence of CD4+ T lymphocytes showing a CD45RO+ phenotype in inflamed 
synovium[8], combined with the association of Human Leukocyte Antigen (HLA) variants to 
disease risk of JIA[9], strongly supports the adaptive immune response in the pathogenesis 
of JIA[10-12]. The role of the innate immune system, and in particular neutrophils, in JIA 
pathogenesis is less clear despite the fact that neutrophils are found at high concentrations 
in JIA synovial fluid[5, 13, 14]. Activated neutrophils play a key role in the pathogenesis of 
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adult and juvenile autoimmune inflammatory diseases (including rheumatoid arthritis (RA) 
and juvenile-onset systemic lupus erythematosus; JSLE) via their ability to release reactive 
oxygen species (ROS), proteases and cytokines, driving the inflammatory process and 
causing damage to host tissues[15-17]. Neutrophils are the most abundant cells within JIA 
synovial fluids, and neutrophil-derived proteases and cytokines, including myeloperoxidase 
(MPO), neutrophil elastase (NE), matrix metalloproteases (MMPs) and interleukin-8 (IL-8), 
have been found at high concentrations at sites of inflammation in adult inflammatory 
arthritis[18-20]. In adult RA, the release of MMP8, MMP9 and NE from neutrophils at the 
pannus-cartilage interface can cause degradation of the collagen matrix[18, 19]. In sJIA, 
levels of neutrophil-derived calgranulins S100A8/9 and S100A12 serve as serum 
biomarkers for the diagnosis of JIA, and correlate with disease activity[21]. pJIA neutrophils 
demonstrate disruption of gene regulatory networks in clusters of genes modulated by IL-8 
and interferon-gamma (IFN-γ)[14], with pJIA neutrophils remaining in an activated state 
even during periods of disease quiescence[14]. 
 
This study hypothesized that neutrophil gene expression signatures would be significantly 
different between JIA patients in comparison to healthy paediatric controls, and that different 
gene expression profiles may be apparent across JIA subtypes. The aim of this study was 
to identify neutrophil gene expression signatures from public microarray datasets, and to 
then validate these gene expression profiles in a new cohort of JIA patients. Here we report 
identification of neutrophil activation signatures in JIA peripheral blood. These include 
expression of neutrophil granule protein genes in PBMCs, elevated numbers of low density 
granulocytes (LDGs) in peripheral blood and increased expression of granule protein genes, 
interleukin-8 and FcγR1B in JIA neutrophils.  
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MATERIAL AND METHODS 
Study population 
The study was approved by North West – Liverpool East Research Ethics Committee. The 
study formed part of the “UK JSLE Cohort Study & Repository” (REC: 6/Q1502/77), and 
written informed patient/parental assent/consent obtained in accordance with the 
declaration of Helsinki. All JIA and healthy control patients were recruited in the study at 
Alder Hey Children’s NHS Foundation Trust in Liverpool, from either outpatient clinics or 
inpatient wards. JIA patients fulfilled the validated criteria endorsed by the International 
League of Associations of Rheumatology, before the age of seventeen[3]. Standard clinical 
data to determine disease activity/current disease state was collected for each of the JIA 
patients. Paediatric healthy controls had no personal or direct family history of rheumatic or 
chronic inflammatory disease, or acute or recent history of infection. Clinical demographics 
for each patient cohort are detailed in Supplementary Table 1. Due to the limited volumes 
of blood available from paediatric patients, we were unable to use the same patient samples 
for each set of experiments, and as such the number of patients analysed within JIA 
subtypes differs for some experiments. 
 
Identifying datasets from public repositories 
Suitable microarray datasets were selected from public repositories: NCBI Gene Expression 
Omnibus (GEO) database and EMBL-EBI Array Express. Key phrases such as “juvenile 
idiopathic arthritis” and “children” were used when performing searches identifying 20 
relevant datasets in GEO and 17 in Array Express. Of these, datasets that had no data on 
systemic juvenile idiopathic arthritis (sJIA) or duplicates datasets between GEO and Array 
express, as well as those that had patients currently on treatment, were manually  
eliminated, providing 2 datasets that could be utilised; E-GEOD-13501[22] and 
GSE21521[23]. However, we noted that the samples for both datasets came from peripheral 
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blood mononuclear cells (PBMC’s) and due to uncertainty of whether a neutrophil signature 
would be found in PBMC’s, an additional dataset which contained samples that were 
collected from whole blood was also added to the list, GSE55319[24] providing an overall 
total of 3 datasets (Supplementary Table 2).   
 
Analysis of Microarray datasets  
Significance analysis of microarrays (SAM) was carried out on the datasets using Multi 
Experiment Viewer (MeV) v4[25] to identify any significantly different gene expression (False 
Discovery Rate adjusted p-value<0.05). Hierarchical cluster analysis was performed in MeV 
using Euclidean clustering and average linkage.   
 
Bioinformatics Analysis 
Bioinformatics analysis of differentially expressed genes (DEG) was carried out using 
Ingenuity Pathway Analysis (IPA). All significant DEG from each data set that could be 
associated with a canonical pathway within Ingenuity knowledge base were analysed, as 
previously described[26, 27].  
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Archived serum samples from 24 JIA patients (sJIA, n=12 and pJIA, n=12) and 12 paediatric 
healthy controls were analysed by ELISA and age and sex matched where possible.  Auto-
antibodies (which may interfere with ELISA antibodies and cause false-positive results) were 
removed by incubating sera in a 96-well plate coated with protein L for 60 minutes 
(ThermoFisher Scientific, Paisley, UK) prior to assay[28]. The concentration of each of the 
proteases was determined using commercially available ELISA kits (purchased from R&D 
systems, Abingdon, UK unless otherwise stated) and protocols provided by the 
manufacturer: NE (PMN Elastase Human ELISA kit, Abcam, Cambridge, UK); MPO; MMP8; 
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MMP9. The serum concentrations of each of the detected proteins were calculated with 
reference to the standard curve, and expressed as nanograms per milliliter (ng/mL).  
 
Cell preparation  
Fresh samples of heparinized blood were used to isolate neutrophils (purity >95%). Briefly, 
at room temperature, whole blood was mixed for 30mins with HetaSepTM (Stemcell, 
Cambridge, UK) at a 5:1 ratio in order to sediment red blood cells. The resulting leukocyte-
rich buffy coat was removed and layered onto Histopaque® (Sigma, Gillingham, UK), and 
centrifuged at 800g for 20 minutes. Separated neutrophils and PBMCs were washed and 
re-suspended in RPMI media. Any contaminating erythrocytes within the neutrophil pellet 
were removed using hypotonic lysis, and cells were resuspended in RPMI media (Life 
Technologies, Paisley, UK). An aliquot of neutrophils and PBMCs were centrifuged at 500g 
for five minutes onto a microscope slide (cytospin) to which Romansky staining (TCS 
Biosciences, Botolph Claydon, UK) was applied, enabling confirmation of purity and 
morphology under a light microscope. Isolated neutrophils and PBMCs were analysed by 
flow cytometry (Beckman coulter FC500 MPL) to determine cell purity, and the presence of 
LDGs within the PBMC population. 10,000 events were analysed. 
 
RNA extraction and qPCR 
RNA was extracted from freshly-isolated neutrophils from fifteen JIA (sJIA n=2, pJIA n=7, 
oJIA n=4, other JIA n=3) and ten HC patients, and PBMCs from 6 JIA (sJIA, n=3, pJIA n=1, 
other JIA n=2) and 4 HC patients using Trizol:chloroform precipitation (Life Technologies, 
Paisley, UK), followed by clean-up using the RNeasy® Mini Kit which included a DNase 
digestion step (Qiagen, Manchester, UK). RNA from each sample was reverse-transcribed 
into cDNA using the Affinity Script cDNA Synthesis kit (Qiagen, Manchester, UK).  qPCR 
was performed using the Brilliant ultra-fast SYBR® green qPCR mastermix (Qiagen, 
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Manchester, UK) and validated primers (Supplementary Table 3) for candidate genes; MPO, 
MMP8, MMP9, NE, IL8 and FCGR1B as well the housekeeping gene, β-actin (ACTB). A 1 
in 5 dilution was used on all DNA samples. PCR reactions took place in MX4000® Multiplex 
Quantitative QPCR system using standard the thermal cycling conditions as follows, 95⁰ C 
for 3 minutes for 1 cycle, followed by 95⁰ C for 30 seconds and 60⁰ C for 1 minute for 40 
cycles. The detection of the SYBR green was calculated and dissociation curve was 
obtained. All mRNA expression values for candidate genes were normalised to that of the 
housekeeping gene[29] using the ΔΔCt method[30]. 
 
Statistical analysis 
Statistical analysis was carried out using GraphPad Prism® (v4). Patient and control data 
was tested for normality using the Kolmogarov-Smirnov test. For data comparing multiple 
groups, the Kruskal-Wallis test was performed, and the Mann-Whitney test when testing 
only two groups. Data was considered statistically significant when p<0.05. 
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RESULTS 
Identification of neutrophil gene expression signatures in JIA microarray datasets 
Significance analysis of microarrays (SAM) was carried out on each of the datasets using 
MultiExperiment Viewer (MeV) identifying significantly different gene expression (DEG, 
q<0.05) between groups i.e. sJIA vs HC, pJIA vs HC, sJIA vs pJIA. The number of DEG up- 
and down-regulated in each dataset is shown in Table 1. 
 
Using IPA®, we carried out bioinformatics analysis of DEG from each dataset to identify 
signalling pathways with different regulation in JIA (Figure 1A). The significant pathways that 
were identified as elevated in JIA included cytokine signalling pathways (IL-8, GM-CSF, 
TGFβ), kinase pathways (JAK/STAT, STAT3, PI3K/AKT, NFκB), pathways relating to cell 
migration (Actin cytoskeleton, Leukocyte extravasation, Integrins), pathways relating to 
production of ROS (production of NO and ROS, phospholipase C) and regulation of cell 
cycle checkpoints.  Upstream regulator analysis was also performed; this is an algorithm 
used by IPA® which examines how many known targets of a transcription regulator (e.g. 
cytokine or transcription factor) are present in the dataset, and compares the direction of 
change to what is expected from the literature in order to predict likely relevant 
transcriptional regulators. In all datasets, granulocyte-colony stimulating factor (G-
CSF/CSF3) was predicted to be regulating the global gene expression signature in JIA 
compared to HC (Supplementary Table 4).  
 
Network analysis was then conducted to identify the relationships between G-CSF and the 
genes in each dataset. The network of G-CSF regulated genes included several genes 
coding for neutrophil granule protein genes, including MPO, MMP8, MMP9 (Figure 1B). 
Further analysis revealed high levels of expression of a number of neutrophil protease genes 
in sJIA patients from two of the datasets (GSE21521 and E-GEOD-13501) as shown in 
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Figure 1C and Table 2. The identification of neutrophil protease genes in sJIA PBMC 
microarray datasets was unexpected as neutrophils isolated by density gradient separation 
do not remain within the PBMC fraction. We hypothesised that the gene signature observed 
was due to the presence of Low Density Granulocytes (LDGs) in the PBMC datasets. LDGs 
have been described in adult and JSLE, as well as RA, as a distinct subset of neutrophils 
with an altered phenotype[31-33].  
 
Identification of LDGs in peripheral blood mononuclear cell fraction of JIA blood 
To determine the presence of LDGs in JIA PBMCs, we collected samples from 16 patients 
with JIA (subtypes, sJIA n=6, pJIA n=3, oJIA n=3 other JIA n=4 of which 6 were on biologics 
and 2 on steroids, See Supplementary Table 1) and 19 HC patients.  Cells were analysed 
by flow cytometry based on forward/side-scatter properties, and those falling within the 
neutrophil gate were considered LDGs.  Cytospins were prepared to confirm the presence 
of cells with neutrophil morphology within PBMC fractions of JIA blood (Figure 2A). The 
number of LDGs was significantly elevated in JIA PBMCs (median (IQ range); n=16, 1.95% 
(1.2-2.4%)) compared to HC PBMCs (n=19, 1.1% (0.4-2.0%)) (Figure 2B, p=0.007).  The 
%LDG was compared to patient ESR, neutrophil count and disease duration; no correlation 
was observed (data not shown). 
 
Measurement of neutrophil proteases in JIA sera 
Transcripts for neutrophil granule proteins including NE, MPO, MMP8 and MMP9 were 
significantly elevated in public datasets for sJIA PBMCs. We therefore measured the level 
of neutrophil proteases present in the sera of JIA patients (sJIA n=12; pJIA n=12; of which 
13 were on biologics, 6 on DMARDs and 12 on steroids, see table S1) compared to age and 
sex-matched healthy paediatric controls. There was no significant difference between the 
study groups (sJIA, pJIA, HC) in serum concentrations of NE (p=0.318), MMP8 (p=0.7), and 
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MPO (p=0.6; Figure 3). However, the levels of MMP9 were significantly different by ANOVA 
between the three study groups (Figure 3, p=0.013). Post-hoc analysis revealed that MMP9 
was significantly lower in sJIA patients (median (IQ range); 93.38ng/ml (41.37-209.8)) 
compared to pJIA (267.0ng/ml (184.8-922.4), p=0.033) and HC (402.2ng/ml (273.2-977.3), 
p=0.007). The levels of MMP9 were not significantly different in pJIA patients compared to 
HC (p=0.235). We observed a positive correlation between the age of the patients and the 
serum levels of NE (p=0.01, Rs=0.4685) and MPO (p=0.03, Rs=0.3641).  
 
Gene expression in JIA neutrophils 
To test the hypothesis that genes for MPO, MMP8, MMP9, and NE are expressed higher in 
JIA compared to HC neutrophils, we isolated mRNA from 15 JIA (subtypes sJIA n=2, pJIA 
n=7, oJIA n=4, other JIA n=2, of which 12 were on biologics and 1 on DMARDS, see table 
S2) and 8 HC neutrophil samples.  qPCR was carried out for each gene and normalised to 
ACTB. Ct values for NE were below the level of detection in JIA and HC neutrophils. 
Transcripts for MMP8 and MPO were significantly higher in JIA neutrophils (Median (IQ 
range); MMP8: (1.47x10-5 (1.02x10-5-2.3x10-5)); MPO: (5.99x10-6 (4.98x10-6-1.85x10-5)) 
compared to HC (MMP8: 2.42x10-6 (1.16x10-6-3.17x10-6)), p=0.001; MPO: (1.41x10-6 
(1.07x10-6-3.51x10-6)), Figure 4A p=0.012). Whilst median MMP9 expression was higher in 
JIA (0.05 (0.03-0.12)) compared to HC (0.03 (0.02-0.05)), this did not reach statistical 
significance (Figure 4A p=0.1).  
 
We also investigated the expression levels of IL-8 and FCGR1B.  The IL8 and GMCSF 
signalling pathway, which activates expression of IL8 in neutrophils[26], were identified by 
IPA® as being elevated in JIA. FCGR1B was chosen as it was identified in all datasets as 
having significantly higher expression, and is directly activated by interferon-γ, a cytokine 
implicated in JIA pathophysiology[14]. Transcripts for IL-8 were expressed across a higher 
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range in JIA compared to HC (Median (IQ range) JIA 0.21 (0.04-0.79), HC 0.26 (0.03-0.46), 
p=0.437). Expression of FCGR1B was significantly higher in JIA (Median (IQ range) JIA 
0.12 (0.006-0.02), HC 0.004 (0.003-0.009), p=0.04, Figure 4B). Finally, we decided to 
measure the expression levels of MPO and MMP8 in PBMCs isolated from 6 JIA (sJIA n=3, 
pJIA n=1, other JIA n=2) and 4 HC patients.  Expression ranges of both genes were higher 
in JIA compared to HC confirming the presence of LDGs within the PBMC fraction of JIA 
leukocytes, although these did not reach statistical significance (Median (IQ range) MPO: 
JIA 0.012 (0.008-0.41), HC 0.02 (0.01-0.04), p=0.895; MMP8: JIA 0.01 (0.008-0.76), HC 
0.008 (0.0009-0.02, p=0.448).   
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DISCUSSION 
In this study we have analysed three publically available datasets to identify neutrophil gene 
expression signatures activated in JIA.  We identified the expression of neutrophil protease 
genes, including NE, MPO, MMP8 and MMP9 in sJIA PBMCs, which indicates the presence 
of LDGs. Whilst LDGs only represent a small percentage of the total PBMC population, work 
by ourselves and others[31, 33] has shown that the expression level of many neutrophil 
granule protein genes is many times higher in LDGs compared to mature neutrophils.[33] 
Similar large increases in expression of neutrophil granule protein genes, including elastase 
and MPO, have been reported in JIA PBMCs and attributed to an innate immune 
signature[34]. We confirmed the presence of LDGs in JIA by analysing samples from a new 
cohort of JIA patients. LDG’s have been described in other rheumatic conditions, including 
SLE and JSLE[31, 32] and RA[33]. These studies have explored LDG functional capacity 
and potential to contribute to clinical manifestations. In adult SLE, LDGs contribute to a 
heightened pro-inflammatory responses and production of interferon (IFN)-α via increased 
neutrophil extracellular trap production (NETosis)[31]. In JSLE, numbers of LDGs correlate 
with disease activity and titres of dsDNA antibodies[32]. In RA, LDGs are less responsive to 
TNF-α and represent a more immature neutrophil phenotype[33].  LDGs have also been 
reported to play a critical role in the pathology of other adult inflammatory diseases, including 
vasculitis and asthma[35, 36]. The presence of LDGs in JIA raises the possibility that these 
cells contribute to the pathophysiology of the disease. However whilst we have confirmed 
the presence of LDGs in JIA peripheral blood, the functional phenotype of these cells in JIA 
remains to be explored.  
 
Neutrophils release serine proteases including NE, MMP8 and MMP9 when inappropriately 
activated during inflammation.  MMPs, a super family of proteases, engage in physiological 
tissue development as well as tissue destruction[37]. By processing pro-forms of cytokines 
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and chemokines they are able to mediate both pro- and anti-inflammatory processes. In 
addition, MMP9 degrades α1-antiproteinase, a potent elastase inhibitor, perpetuating the 
inflammatory response[37]. Regulated by tissue inhibitors of MMP’s (TIMPs), enzymes 
MMP8 and MMP9 are released by neutrophils following migration to the site of inflammation. 
Observations have shown an imbalance between TIMPs and MMP-8/9 leads to pathological 
tissue destruction. Indeed both MMP8 and MMP9 are found at high concentrations in 
synovial fluid of adult patients with RA[38, 39].  Both MMP8 and MMP9 cleave components 
of the collagen matrix within the joint, including collagen V, Vii and X, aggrecan, and 
fibronectin[40]. Surprisingly, we found that levels of neutrophil proteases in the sera of sJIA 
and pJIA patients were not elevated compared to healthy controls. Moreover, MMP9 levels 
were significantly lower in JIA patients compared to controls, and were significantly lower in 
sJIA compared to pJIA. There may be several explanations for this observation: firstly, the 
ELISA assays used in our study measured the concentration of the proteases in serum, but 
did not measure enzyme activity; secondly, whilst there is evidence for elevated protease 
levels at the site of inflammation (synovial joints) in adult RA[18, 38, 39], it is unclear whether 
these proteases are elevated in sera; thirdly, the results may be explained by the 
heterogeneous nature of JIA subtypes; finally, all JIA patients in our study were receiving 
medication, with many receiving biologic and/or disease-modifying therapies, and as such 
this places limitations on the interpretation of our data. Studies have determined that levels 
of neutrophil-derived proteases can be affected by anti-inflammatory therapies. A 
longitudinal study showed lower levels of MMP9 in a subset of pJIA patients following a year 
of treatment with the TNF inhibitor etanercept[41]. The blockade of cytokine and chemokine 
synthesis in both peripheral blood cells and synovial tissue caused by TNF inhibitor therapy 
leads to lower levels of serum proteases[41, 42]. Similarly, tocilizumab, a humanised, 
monoclonal, IL-6 receptor (IL-6R) antibody used in the treatment of sJIA, indirectly 
decreases levels of MMP9[43]. The use of drugs such as methotrexate in other inflammatory 
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conditions such as RA has been reported to reduce levels of cytokines such as IL-8 in the 
serum [44, 45]. Unfortunately it is not possible to comment on the effect of treatment on LDG 
expression in our study, due to the small sample size; only one of the patients was not on 
medication and the majority were receiving biologics.  
 
The level of expression of genes for neutrophil granule proteins NE, MPO, MMP8 and MMP9 
were higher in neutrophils from all JIA subtypes compared to HC, although the levels differed 
across the JIA patient cohort due to the heterogeneous nature of this condition. This 
observation could be partially explained by suppressed immune activity during therapy. 
However, a recent study found that gene expression in JIA neutrophils remains in state of 
activation despite response to treatment[46].  Mature adult neutrophils do not normally 
express transcripts for neutrophil granule proteins; expression of genes such as MPO and 
NE are down-regulated during terminal differentiation of neutrophils prior to release from the 
bone marrow[47]. However, expression of neutrophil granule protein genes including MPO 
and NE by mature neutrophils has recently been reported in a population of RA patients, 
and is associated with a lack of response of RA patients to TNF inhibitor therapy[48]. 
Elevated transcripts for NE, MPO, MMP8 and MMP9 were identified in public datasets from 
sJIA PBMCs, and whilst this indicates the expression of these genes by LDGs within the 
PBMC fraction, it gives no information on whether these genes are elevated in JIA 
neutrophils. 
 
CD64 is an interferon-γ-regulated Fcγ receptor sub-class, encoded by three genes 
(FCGR1A, FCGR1B, FCGR1C)[49, 50].  Neutrophil FCGR1A binds monomeric IgG and is 
classed as a high-affinity IgG receptor. Whilst FCGR1B and FCGR1C are commonly 
believed to be pseudogenes[51] lacking the extracellular immunoglobulin-like domain coded 
by exon 3[52], a splice variant of FCGR1B has been shown to bind aggregated immune-
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complexes formed by IgG[53]. A possible role for a secreted soluble FcγR1b receptor splice 
variant has also been proposed[52]. Transcripts for FCGR1A were elevated in all public 
datasets analysed in this study, but not validated by qPCR. Increased expression of the 
FCGR1B transcript of CD64 by JIA neutrophils has not been previously described and is 
reported here for the first time.  In adult RA, CD64 is expressed at high amounts in 
neutrophils aspirated from synovial joints, and expression can be induced in HC neutrophils 
by the addition of interferon-γ or cell-free RA synovial fluid[54]. Neutrophils expressing the 
CD64 receptor can be activated by monomeric IgG to produce a respiratory burst (ROS), 
implicated in damage to host tissue in inflammatory diseases such as RA and COPD[15, 
16, 50]. Expression of FCGR1B by neutrophils in JIA could therefore provide insight into the 
disease pathology, particularly in those pJIA patients who are rheumatoid factor positive. Of 
note, FCGR1B expression was higher in the pJIA patients when we analysed the dataset 
by JIA subtype. However, further investigation of CD64 protein expression is required to 
confirm the role of FCGR1B in the pathology of JIA.  
 
In summary, we describe here for the first time a neutrophil activation signature in JIA 
patients, which is due in part to the presence of elevated numbers of LDGs.  Neutrophils 
from JIA patients have elevated transcription of genes encoding granule proteins, including 
MMP8, MMP9 and MPO, as well as IL-8 and the high-affinity IgG receptor CD64. This 
activation signature has important potential implications for disease pathology in JIA, as the 
release of proteases and reactive oxygen metabolites (in response to activation of FcγRs) 
is a major cause of systemic inflammation and damage to joints. 
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TABLES 
 
Table 1: Number of significantly up- and down-regulated genes identified in each dataset 
using significance analysis of microarrays (SAM) (FDR<0.05) 
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Significant genes 454 5 795 384 4 518 248 
- Up-regulated  421 1 654 281 3 477 56 
- Down-regulated  33 4 41 103 1 41 192 
Non-significant genes 23064 23513 22723 23135 23515 23001 28651 
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Table 2. Neutrophil granule protein genes with significant levels of gene expression in JIA 
microarray datasets from PBMCs (E-GEOD-13501, GSE21521) and whole blood 
(GSE55139) (data shown as Log2(Fold change), N.S.=not significant). 
 
Gene Name E-GEOD-13501 
sJIA v HC 
GSE21521 
sJIA v pJIA 
GSE21521 
sJIA v HC 
GSE55319 
pJIA v HC 
AZU1 N.S. N.S. N.S. N.S. 
BPI 4.05 3.88 N.S. N.S. 
CAMP 3.01 2.98 N.S. N.S. 
CEACAM1 3.59 3.30 3.58 N.S. 
CEACAM8 N.S. 3.25 N.S. N.S. 
CLU 2.19 N.S. 2.26 N.S. 
CRISP3 4.08 4.13 N.S. N.S. 
CTSA 1.36 N.S. 1.37 N.S. 
CTSG N.S. N.S. N.S. N.S. 
DEFA4 4.33 4.58 N.S. N.S. 
ELANE 3.04 2.69 N.S. N.S. 
LCN2 4.65 4.03 4.50 N.S. 
LTF 4.30 4.57 N.S. N.S. 
MMP8 6.94 7.23 6.67 N.S. 
MMP9 5.74 4.82 5.75 N.S. 
MPO 3.12 2.86 2.77 N.S. 
RNASE2 2.00 N.S. 2.14 N.S. 
RNASE3 3.14 3.20 N.S. N.S. 
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FIGURE LEGENDS 
Figure 1. Ingenuity analysis of significant genes identified in public datasets for JIA. 
(A) Canonical pathways predicted to have significantly differential regulation in each dataset. 
All pathways predicted to have increased activation in JIA except Cell cycle: G2/M DNA 
damage checkpoint regulation, PTEN signaling, RhoGDI signaling, and Cell Cycle: CHK 
proteins checkpoint control, which were predicted to have decreased activation. (B) Network 
of genes regulated by G-CSF (CSF3) in JIA. Network is overlaid with expression data for 
dataset E-GEOD-13501 (sJIA v HC) as an example. The intensity of the red shading 
correlates to up-regulation of the gene in sJIA vs HC. (C) Heatmap of genes for neutrophil 
granule proteins that were identified as being significantly up-regulated in the datasets  
Expression levels: Red=high; Black=median; Green=low. 
 
Figure 2. Identification of low density granulocytes (LDGs) in JIA peripheral blood.  
(A) LDGs were identified in JIA (n=16) and HC (n=19) PBMCs by forward/side scatter 
properties, and cell morphology on cytospin (white arrow). (B) The number of LDGs in JIA 
PBMCs was significantly higher than in HC PBMCs (** p=0.007). Bars represent median ± 
interquartile range. 
 
Figure 3. Levels of neutrophil granule proteins in JIA and HC sera.  Levels of NE, MPO, 
MMP8 and MMP9 were measured in serum samples from age/sex-matched patients with 
sJIA, pJIA and HC (n=12 in each group).  MMP9 levels were significantly lower in sJIA 
compared to HC (** p=0.007). Bars represent median ± interquartile range. 
 
Figure 4. Gene expression in JIA neutrophils. (A) The expression of genes for neutrophil 
granule proteins MPO (p=0.012), MMP8 (p=0.001) and MMP9 (p=0.1) was higher in JIA 
neutrophils compared to HC (JIA n=15, HC n=8). (B) Expression levels of IL8 and FCGR1B 
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were also higher in JIA neutrophils compared to HC (* p=0.04). Bars represent median ± 
interquartile range. Gene expression shown as mean normalized expression (MNE), 
normalized to actin (ACTB).  
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Figure 1 
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Figure 4 
